POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer | Prof Johan Vansteenkiste at ECC 2015

At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy, safety and predictive biomarkers from POPLAR, a randomised phase 2 clinical trial of atezolizumab monotherapy versus docetaxel in patients with second- or third-line non-small cell lung cancer.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews